-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Assenagon Asset Management S.A. Buys 11,527 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Assenagon Asset Management S.A. Buys 11,527 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Assenagon Asset Management S.A. grew its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 8.5% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 147,636 shares of the biotechnology company's stock after acquiring an additional 11,527 shares during the quarter. Assenagon Asset Management S.A. owned about 0.10% of Ironwood Pharmaceuticals worth $1,530,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of IRWD. Gladius Capital Management LP bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at $55,000. Banque Cantonale Vaudoise bought a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at $58,000. Captrust Financial Advisors lifted its position in shares of Ironwood Pharmaceuticals by 441.7% during the 2nd quarter. Captrust Financial Advisors now owns 6,690 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 5,455 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter valued at $78,000. Finally, Quantbot Technologies LP bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter worth $109,000.
Get Ironwood Pharmaceuticals alerts:Insiders Place Their Bets
In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 110,962 shares of the company's stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $12.07, for a total value of $1,339,311.34. Following the completion of the transaction, the chief executive officer now owns 712,440 shares of the company's stock, valued at approximately $8,599,150.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 13.10% of the company's stock.
Ironwood Pharmaceuticals Price Performance
Shares of IRWD stock opened at $11.59 on Friday. The company has a quick ratio of 25.78, a current ratio of 25.78 and a debt-to-equity ratio of 0.67. Ironwood Pharmaceuticals, Inc. has a twelve month low of $9.73 and a twelve month high of $12.95. The company has a market cap of $1.78 billion, a P/E ratio of 12.20 and a beta of 0.96. The business has a fifty day simple moving average of $11.90 and a 200 day simple moving average of $11.39.Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%. The business had revenue of $108.64 million during the quarter, compared to the consensus estimate of $111.51 million. On average, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.01 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 17th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $14.67.
About Ironwood Pharmaceuticals
(Get Rating)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
Read More
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
据纳斯达克在最近提交给美国证券交易委员会的文件中称,Assenagon Asset Management S.A.第三季度增持了铁木制药股份有限公司8.5%的股份。该公司在本季度额外收购了11,527股后,持有这家生物技术公司147,636股股票。截至最近提交的美国证券交易委员会申报文件,Assenagon Asset Management S.A.持有铁木制药约0.10%的股份,价值1,53万美元。
其他一些机构投资者最近也调整了对IRWD的持股。Gladius Capital Management LP在第二季度购买了Ironwood PharmPharmticals的新股,价值5.5万美元。Canonale Vaudoise银行在第二季度购买了Ironwood PharmPharmticals的新股,价值5.8万美元。CapTrust Financial Advisors在第二季度将其在Ironwood PharmPharmticals的股票头寸提高了441.7%。CapTrust Financial Advisors在此期间额外购买了5455股,现在拥有6690股这家生物技术公司的股票,价值7.7万美元。Lazard Asset Management LLC在第一季度购买了Ironwood PharmPharmticals的新股,价值7.8万美元。最后,Quantbot Technologies LP在第一季度购买了价值10.9万美元的Ironwood PharmPharmticals新股。
到达铁木制药警报:内部人士下注
在Ironwood PharmPharmticals的其他消息中,首席执行官托马斯·A·麦考特在日期为1月5日星期四的交易中出售了110,962股公司股票。这只股票的平均售价为12.07美元,总价值为1,339,311.34美元。交易完成后,首席执行官现在拥有该公司712,440股股票,价值约8,599,150.80美元。这笔交易是在提交给美国证券交易委员会的法律文件中披露的,该文件可通过美国证券交易委员会网站。内部人士持有该公司13.10%的股份。
铁木制药的价格表现
周五,IRWD的股票开盘报11.59美元。该公司的速动比率为25.78,流动比率为25.78,债务权益比率为0.67。Ironwood PharmPharmticals,Inc.的12个月低点为9.73美元,12个月高位为12.95美元。该公司市值为17.8亿美元,市盈率为12.20倍,贝塔系数为0.96。该业务的50日简单移动均线切入位为11.90美元,200日简单移动均线切入位为11.39美元。铁木制药(纳斯达克代码:IRWD-GET Rating)上一次公布季度收益数据是在11月3日星期四。这家生物技术公司公布本季度每股收益为0.28美元,比普遍预期的0.27美元高出0.01美元。Ironwood PharmPharmticals的股本回报率为30.24%,净利润率为39.85%。该业务本季度的收入为1.0864亿美元,而普遍预期为1.1151亿美元。卖方分析师平均预测,Ironwood PharmPharmticals,Inc.本财年每股收益为1.01欧元。
华尔街分析师预测经济增长
另外,StockNews.com在12月17日(星期六)的一份研究报告中将Ironwood PharmPharmticals的评级从“强力买入”下调至“买入”。一名分析师对该股的评级为持有,三名分析师对该公司的评级为买入。根据MarketBeat.com的数据,该股目前的平均评级为“中等买入”,共识目标价为14.67美元。
铁木制药公司简介
(获取评级)
Ironwood PharmPharmticals,Inc.是一家保健公司,专注于胃肠(GI)产品的开发和商业化。它在美国和墨西哥以Linzess的名义销售利纳克肽,在加拿大和欧盟以Constella的名义销售利纳克肽,这是一种鸟苷环化酶C型激动剂,用于治疗患有便秘(IBS-C)或慢性特发性便秘(CIC)的成年人。
阅读更多内容
- 免费获取StockNews.com关于铁木制药的研究报告(IRWD)
- MarketBeat:回顾中的一周01/09-01/13
- 摩根大通破产,银行为衰退做好准备
- 为什么Bed Bath&Beyond的股价上涨了261%?
- Roku股价走势,原因如下
- Carvana Stock Rally,这是你需要知道的
接受Ironwood PharmPharmticals Daily新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ironwood PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧